Literature DB >> 20524207

Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity.

Errol Wijelath1, Mayumi Namekata, Jacqueline Murray, Mai Furuyashiki, Siyuan Zhang, Daniel Coan, Masahiro Wakao, Robert B Harris, Yasuo Suda, Lianchun Wang, Michael Sobel.   

Abstract

Heparin and heparin-like molecules are known to modulate the cellular responses to vascular endothelial growth factor-A (VEGF-A). In this study, we investigated the likely mechanisms for heparin's influence on the biological activity of VEGF-A. Previous studies have shown that exogenous heparin's effects on the biological activity of VEGF-A are many and varied, in part due to the endogenous cell-surface heparan sulfates. To circumvent this problem, we used mutant endothelial cells lacking cell-surface heparan sulfates. We showed that VEGF-induced cellular responses are dependent in part on the presence of the heparan sulfates, and that exogenous heparin significantly augments VEGF's cellular effects especially when endogenous heparan sulfates are absent. Exogenous heparin was also found to play a cross-bridging role between VEGF-A(165) and putative heparin-binding sites within its cognate receptor, VEGFR2 when they were examined in isolation. The cross-bridging appears to be more dependent on molecular weight than on a specific heparin structure. This was confirmed by surface plasmon resonance binding studies using sugar chips immobilized with defined oligosaccharide structures, which showed that VEGF-A(165) binds to a relatively broad range of sulfated glycosaminoglycan structures. Finally, studies of the far-UV circular dichroism spectra of VEGF-A(165) showed that heparin can also modulate the conformation and secondary structure of the protein.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20524207      PMCID: PMC3175432          DOI: 10.1002/jcb.22727

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  34 in total

1.  Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.

Authors:  A M Dougher; H Wasserstrom; L Torley; L Shridaran; P Westdock; R E Hileman; J R Fromm; R Anderberg; S Lyman; R J Linhardt; J Kaplan; B I Terman
Journal:  Growth Factors       Date:  1997       Impact factor: 2.511

2.  Structural features in heparin that interact with VEGF165 and modulate its biological activity.

Authors:  K Ono; H Hattori; S Takeshita; A Kurita; M Ishihara
Journal:  Glycobiology       Date:  1999-07       Impact factor: 4.313

3.  Structural aspects of heparin responsible for interactions with von Willebrand factor.

Authors:  L F Poletti; K E Bird; D Marques; R B Harris; Y Suda; M Sobel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-05       Impact factor: 8.311

4.  Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses.

Authors:  Lianchun Wang; Mark Fuster; P Sriramarao; Jeffrey D Esko
Journal:  Nat Immunol       Date:  2005-07-31       Impact factor: 25.606

5.  Cysteine proteinase activity regulation. A possible role of heparin and heparin-like glycosaminoglycans.

Authors:  P C Almeida; I L Nantes; C C Rizzi; W A Júdice; J R Chagas; L Juliano; H B Nader; I L Tersariol
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

6.  Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins.

Authors:  Satoko Ashikari-Hada; Hiroko Habuchi; Yutaka Kariya; Koji Kimata
Journal:  J Biol Chem       Date:  2005-07-15       Impact factor: 5.157

7.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells.

Authors:  N Koyama; M G Kinsella; T N Wight; U Hedin; A W Clowes
Journal:  Circ Res       Date:  1998-08-10       Impact factor: 17.367

Review 9.  Angiogenesis: update 2005.

Authors:  H F Dvorak
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 10.  Vascular endothelial growth factor (VEGF) and its receptors.

Authors:  G Neufeld; T Cohen; S Gengrinovitch; Z Poltorak
Journal:  FASEB J       Date:  1999-01       Impact factor: 5.191

View more
  16 in total

1.  Heparan sulfate deficiency disrupts developmental angiogenesis and causes congenital diaphragmatic hernia.

Authors:  Bing Zhang; Wenyuan Xiao; Hong Qiu; Fuming Zhang; Heather A Moniz; Alexander Jaworski; Eduard Condac; Gerardo Gutierrez-Sanchez; Christian Heiss; Robin D Clugston; Parastoo Azadi; John J Greer; Carl Bergmann; Kelley W Moremen; Dean Li; Robert J Linhardt; Jeffrey D Esko; Lianchun Wang
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

2.  High-resolution probing heparan sulfate-antithrombin interaction on a single endothelial cell surface: single-molecule AFM studies.

Authors:  Cunlan Guo; Xian Fan; Hong Qiu; Wenyuan Xiao; Lianchun Wang; Bingqian Xu
Journal:  Phys Chem Chem Phys       Date:  2015-05-28       Impact factor: 3.676

3.  Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin- and CXCL12 protein-mediated leukocyte trafficking in mice.

Authors:  Siyuan Zhang; Eduard Condac; Hong Qiu; Junlin Jiang; Gerardo Gutierrez-Sanchez; Carl Bergmann; Tracy Handel; Lianchun Wang
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

4.  Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling.

Authors:  Fabiola Cecchi; Deborah Pajalunga; C Andrew Fowler; Aykut Uren; Daniel C Rabe; Benedetta Peruzzi; Nicholas J Macdonald; Davida K Blackman; Stephen J Stahl; R Andrew Byrd; Donald P Bottaro
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

Review 5.  Customizable biomaterials as tools for advanced anti-angiogenic drug discovery.

Authors:  Eric H Nguyen; William L Murphy
Journal:  Biomaterials       Date:  2018-07-26       Impact factor: 12.479

6.  Heparin-Poloxamer Thermosensitive Hydrogel Loaded with bFGF and NGF Enhances Peripheral Nerve Regeneration in Diabetic Rats.

Authors:  Rui Li; Yiyang Li; Yanqing Wu; Yingzheng Zhao; Huanwen Chen; Yuan Yuan; Ke Xu; Hongyu Zhang; Yingfeng Lu; Jian Wang; Xiaokun Li; Xiaofeng Jia; Jian Xiao
Journal:  Biomaterials       Date:  2018-03-26       Impact factor: 12.479

7.  Quantitative phosphoproteomics analysis reveals broad regulatory role of heparan sulfate on endothelial signaling.

Authors:  Hong Qiu; Jun-Lin Jiang; Miao Liu; Xin Huang; Shi-Jian Ding; Lianchun Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-06       Impact factor: 5.911

8.  Heparan sulfate inhibits transforming growth factor β signaling and functions in cis and in trans to regulate prostate stem/progenitor cell activities.

Authors:  Sumit Rai; Omar Awad Alsaidan; Hua Yang; Houjian Cai; Lianchun Wang
Journal:  Glycobiology       Date:  2020-05-19       Impact factor: 4.313

9.  Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational Model.

Authors:  Lindsay Wendel Clegg; Feilim Mac Gabhann
Journal:  PLoS Comput Biol       Date:  2015-06-12       Impact factor: 4.475

10.  Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer.

Authors:  Jingwen Yue; Weihua Jin; Hua Yang; John Faulkner; Xuehong Song; Hong Qiu; Michael Teng; Parastoo Azadi; Fuming Zhang; Robert J Linhardt; Lianchun Wang
Journal:  Front Mol Biosci       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.